This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
AI, Cancer Vaccines, and Next-Gen Medicine
by Neena Mishra
Could cancer vaccines and AI drive the next wave of healthcare innovation?
AMN Healthcare Services (AMN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 4.30% and 0.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cue Health Inc. (HLTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 28.89% and 6.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of -21.88% and 31.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Augmedix, Inc. (AUGX) Soars 7.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Augmedix, Inc. (AUGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cue Health Inc. (HLTH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 3.77% and 10.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cue Health Inc. (HLTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Cue Health Inc. (HLTH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Cue Health Inc. (HLTH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cue Health Inc. (HLTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cue Health Inc. (HLTH) Loses -47.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Cue Health Inc. (HLTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cue Health Inc. (HLTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 21.82% and 19.92%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?